Critical Survey: AngioDynamics (NASDAQ:ANGO) versus GlucoTrack (NASDAQ:GCTK)

GlucoTrack (NASDAQ:GCTK) and AngioDynamics (NASDAQ:ANGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.

Insider & Institutional Ownership

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 89.4% of AngioDynamics shares are held by institutional investors. 8.4% of GlucoTrack shares are held by insiders. Comparatively, 6.0% of AngioDynamics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for GlucoTrack and AngioDynamics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1	0	0	0	1.00
AngioDynamics	2	0	2	1	2.40

AngioDynamics has a consensus price target of $19.50, suggesting a potential upside of 29.65%. Given AngioDynamics’ stronger consensus rating and higher probable upside, analysts clearly believe AngioDynamics is more favorable than GlucoTrack.

Profitability

This table compares GlucoTrack and AngioDynamics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
AngioDynamics	-11.48%	-5.73%	-3.77%

Valuation & Earnings

This table compares GlucoTrack and AngioDynamics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39 million	($18.04)	-0.03
AngioDynamics	$320.17 million	1.94	-$36.74 million	($0.87)	-17.29

GlucoTrack has higher earnings, but lower revenue than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

GlucoTrack has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.

Summary

AngioDynamics beats GlucoTrack on 9 of the 14 factors compared between the two stocks.

About GlucoTrack

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

About AngioDynamics

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.